ClinicalTrials.Veeva

Menu

CELTIC Bifurcation Study

E

European Cardiovascular Research Institute (ECRI)

Status

Unknown

Conditions

Coronary Bifurcations

Study type

Observational

Funder types

NETWORK
Industry

Identifiers

Details and patient eligibility

About

This study will examine outcomes for patients treated by planned culotte stenting and compare outcomes with 2 different stent platforms, the next generation Synergy II and the Xience Xpedition DES platforms.

Enrollment

170 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female patient >18 years old
  • Females of childbearing potential with a negative pregnancy test
  • Coronary artery disease requiring revascularization that is amenable to PCI
  • Medina 1,1,1 bifurcation lesion [13] with >70% lesion in both the main vessel and the side branch by visual assessment
  • Main branch and side branch ≥ 2.5mm in diameter by visual assessment
  • Both vessels require stenting in the opinion of the operator

Exclusion criteria

  • Acute myocardial infarction with ongoing ST-elevation
  • Cardiogenic shock
  • Lesion involves the left main coronary artery
  • Lesion involves bypass graft
  • Plan to treat >1 other coronary vessel at the time of inclusion
  • Chronic total occlusion of any target vessel
  • Left ventricular ejection fraction <20%
  • Requirement for ongoing haemodialysis
  • Life-expectancy limited to <12 months due to co-morbid condition
  • Known allergy to Aspirin
  • Known allergy to Clopidorel and Prasugrel and Ticagrelor
  • Known allergy to stent drug elutant
  • Known allergy to any other component of either the Synergy II or Xience Xpedition stents systems
  • Ongoing participation in another investigational device or drug study
  • Inability to provide informed consent

Trial contacts and locations

6

Loading...

Central trial contact

David Foley

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems